| Old Articles: <Older 8121-8130 Newer> |
|---|
 |
The Motley Fool
December 9, 2011
David Williamson |
1 Biotech Soars While Another Crashes Cell Therapeutics dilutes shareholders while SIGA squashes fears.   |
The Motley Fool
December 9, 2011
Paul Chi |
3 Europe-Proof Stocks for Your Portfolio These health-care stocks are Europe-proof. |
The Motley Fool
December 9, 2011
Harsh Chauhan |
Medtronic Regains Its Footing Medtronic comes up with a strong quarter. |
The Motley Fool
December 9, 2011
Marthe LaRosiliere |
Intuitive Surgical: Plenty of Room to Grow The surgical-robot maker is nearly a 10-bagger since 2005, but its future remains bright. |
The Motley Fool
December 8, 2011
Brian Orelli |
A Soaring Biotech With Room to Run Affymax gets a leg up from an FDA advisory panel vote. |
Chemistry World
December 8, 2011
Sarah Houlton |
Academia Grows Its Role in Drug Discovery The number of pharma patents being filed by universities around the world is soaring compared with those coming from industry. |
Chemistry World
December 8, 2011
Maria Burke |
Government Launches UK Life Sciences Strategy Prime minister David Cameron has announced a package of measures designed to boost the UK's life sciences industry. |
The Motley Fool
December 8, 2011
Luke Timmerman |
Affymax Passes FDA Panel Scrutiny, Looks to Challenge Amgen Anemia Drug Many investors wrote off Affymax in June 2010, but was that premature? |
The Motley Fool
December 8, 2011
Rebecca Lipman |
Smart Money Picks: Biotech Stocks With Bullish Short Trends Do you agree with short-sellers' optimism for these names? |
The Motley Fool
December 8, 2011
Dan Caplinger |
Has Geron Become the Perfect Stock? Geron has a modest pipeline of cancer drugs, including imetelstat, which is currently in phase 2 clinical trials. |
| <Older 8121-8130 Newer> Return to current articles. |
